# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA1614018 | F | PUBCHEM_BIOASSAY: Inhibitors of Bacterial Quorum Sensing Structure Activity Relationship (SAR) Analysis: Dose Response Assay. (Class of assay: confirmatory) [Related pubchem assays: 700, 527 ] | Staphylococcus aureus | 32 | organism-based format | PubChem BioAssays | ||
2. | ALA2339943 | B | Inhibition of Staphylococcus aureus AgrC1 | Staphylococcus aureus | 23 | assay format | Scientific Literature | ||
3. | ALA4257239 | B | Inhibition of mouse Eya3 catalytic domain (223 to 510 residues) by p-nitrophenylphosphate assay | Mus musculus | 3 | assay format | Patent Bioactivity Data | ||
4. | ALA4257240 | B | Inhibition of human Eya3 isoform 2 (127 to 573 residues) incubated for 30 mins by p-nitrophenylphosphate assay | Homo sapiens | 14 | assay format | Patent Bioactivity Data | ||
5. | ALA4257242 | B | Inhibition of PTP1B (unknown origin) by p-nitrophenylphosphate assay | Homo sapiens | 3 | single protein format | Patent Bioactivity Data | ||
6. | ALA4257252 | B | Selectivity index, ratio of IC50 for inhibition of PTP1B (unknown origin) by p-nitrophenylphosphate assay to IC50 for inhibition of mouse Eya3 catalytic domain (223 to 510 residues) by p-nitrophenylphosphate assay | 3 | assay format | Patent Bioactivity Data | |||
7. | ALA4257253 | B | Inhibition of Eya2 (unknown origin) expressed in human MCF10A cells assessed as reduction in cell migration | Homo sapiens | 3 | cell-based format | Patent Bioactivity Data | ||
8. | ALA4257255 | B | Inhibition of Eya2 D250N mutant (unknown origin) expressed in human MCF10A cells assessed as reduction in cell migration | Homo sapiens | 3 | cell-based format | Patent Bioactivity Data | ||
9. | ALA4257256 | T | Toxicity in human MCF10A cells expressing Eya2 (unknown origin) assessed as effect on cell proliferation of | Homo sapiens | 3 | cell-based format | Patent Bioactivity Data | ||
10. | ALA4257267 | F | Inhibition of cell motility of HUVEC | Homo sapiens | 3 | cell-based format | Patent Bioactivity Data | ||
11. | ALA4257268 | T | Toxicity in HUVEC assessed as effect on cell proliferation by MTT assay | Homo sapiens | 3 | cell-based format | Patent Bioactivity Data | ||
12. | ALA4257271 | F | Inhibition of tubulogenesis of HUVEC grown on growth factor-reduced matrigel at 7.5 uM by inverted microscopy | Homo sapiens | 2 | cell-based format | Patent Bioactivity Data | ||
13. | ALA4257272 | F | Inhibition of endothelial cell migration in VEGF165-stimulated C57BL16 mouse aortic rings incubated in collagen matrix assessed as induction of shorter sprouts incubated for 10 days by aortic ring assay | Mus musculus | 3 | tissue-based format | Patent Bioactivity Data | ||
14. | ALA4257273 | F | Inhibition of endothelial cell migration in VEGF165-stimulated C57BL16 mouse aortic rings incubated in collagen matrix assessed as reduction in microvascular density incubated for 10 days by aortic ring assay | Mus musculus | 3 | tissue-based format | Patent Bioactivity Data | ||
15. | ALA4257274 | F | Inhibition of angiogenesis in FLK1-GFP trangenic zebrafish model of angiogenesis assessed as induction of defects in developing vasculature measured after 24 hpf stage by fluorescence microscopy | Danio rerio | 3 | organism-based format | Patent Bioactivity Data | ||
16. | ALA4257275 | F | Inhibition of angiogenesis in FLK1-GFP trangenic zebrafish model of angiogenesis assessed as reduction in intersegmental vessel number and extension measured after 24 hpf stage by fluorescence microscopy | Danio rerio | 3 | organism-based format | Patent Bioactivity Data | ||
17. | ALA4257276 | F | Inhibition of angiogenesis in FLK1-GFP trangenic zebrafish model of angiogenesis assessed as effect on vasculature exposed to compound starting at later stage (20 hpf) by fluorescence microscopy | Danio rerio | 3 | organism-based format | Patent Bioactivity Data | ||
18. | ALA4257278 | F | Inhibition of proliferative retinopathy in mouse model of oxygen-induced retinopathy assessed as reduction in formation of neovascular tufts at 50 to 100 pmole injected at P12 and measured at P16 | Mus musculus | 3 | organism-based format | Patent Bioactivity Data | ||
19. | ALA4257279 | F | Inhibition of proliferative retinopathy in mouse model of oxygen-induced retinopathy assessed as reduction in revascularization into the vaso-obliterated area at 50 to 100 pmole injected at P12 and measured at P16 | Mus musculus | 3 | organism-based format | Patent Bioactivity Data | ||
20. | ALA4422500 | B | Inhibition of mouse Eya3 catalytic domain (223 to 510 residues) using para-nitrophenol phosphate substrate incubated for 30 mins | Mus musculus | 3 | single protein format | Patent Bioactivity Data |